156-585 test - CheckPoint Certified Troubleshooting Expert Updated: 2023

Elle Smith has been an advertising professional for more than 25 years. Her work for ABC, CBS and Sony Pictures Television has appeared on radio, on air, in print and outdoors. In addition, Smith has more than 20 years experience in marketing, graphic arts, commercial photography and print production, and is a licensed real estate agent with property management certification in California.

Jane Williams began her writing career in 2000 as the writer and editor of a nationwide marketing company. Her articles have appeared on various websites. Williams briefly attended college for a degree in administration before embarking on her writing career.

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a benefit.

The INTERLINK-1 trial was testing monalizumab – an NKG2A receptor inhibitor – in combination with EGFR-targeting antibody cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with PD-1/PD-L1-targeted immunotherapies.

AZ licensed rights to monalizumab (formerly IPH2201) from France's Innate Pharma in 2018, after taking an option on the drug four years earlier in a deal that included an upfront payment of $250 million plus milestone payments, including $100 million due on the start of phase 3 testing.

Shares in Innate Pharma started to slide after this morning's announcement and were down almost 17% at the time of writing.

NKG2A is a checkpoint receptor thought to inhibit the anticancer activity of natural killer (NK) and cytotoxic CD8+ T-cells.

The results of INTERLINK-1 run counter to encouraging findings in a single-arm phase 1b/2 trial of monalizumab/cetuximab in SCHHN patients, which showed an overall response rate of 27.5% with the combination, as well as progression-free survival of five months and overall survival of more than ten months when after PD-1/PD-L1 therapy.

AZ is still testing the drug in the phase 3 PACIFIC-9 trial, looking at its PD-L1 checkpoint inhibitor Imfinzi (durvalumab) plus either monalizumab or anti-CD73 monoclonal antibody oleclumab in patients with non-small cell lung cancer (NSCLC) who have not progressed after first-line chemoradiotherapy.

It is also being tested alongside Imfinzi in phase 2 across multiple solid tumour types, including in the NeoCOAST-2 study as neoadjuvant (pre-surgery) treatment for early-stage lung cancer.

"While we are disappointed with the outcome of this study, the findings are certain to advance our understanding of the role of immunotherapy in this setting," said Mondher Mahjoubi, Innate Pharma's chief executive.

"We remain confident in the development program for monalizumab in lung cancer, where encouraging data has been previously reported from the randomized, Phase 2 COAST and Neo-COAST studies," he added.

This service is provided by our Division of Oral and Maxillofacial Pathology. It involves the monitoring of heat sterilizers using a biologic indicator to test the effectiveness of the sterilizer in killing microbial life, and is the only true test of effective sterilization.

Subscribers to the service receive a year's supply of test forms and biologic indicator test strips and control strips. The biologic indicators are filter paper strips impregnated with spores of Geobacillus stearothermophilus and Bacillus atrophaeus enclosed in a glassine envelope.

Process

• The biological indicator is placed in a typical sterilization load.
• At the end of the sterilization cycle, the biologic indicator test along with an unprocessed control is mailed to the monitoring service for culturing.
• Positive results, indicative of ineffective sterilization, are called to the office immediately and are Verified by a gram stain.

What we offer

• biologic monitoring of autoclaves, chemiclaves and dry heat sterilizers
• steam sterilization results in 24 hours
• quality assurance by an independent laboratory
• help with troubleshooting
• test results will be emailed directly to your office
  
• total confidentiality

Results

After 19 years of operation, we've performed more than 30,000 routine tests for subscribers. Sterilizers tested include autoclaves, chemiclaves and dry heat sterilizers.

Failed tests are repeated, and if the retest is again positive, equipment malfunction is indicated and servicing followed by another test is recommended. If the first retest is negative, a load processing problem is indicated.

Routine biologic monitoring by subscribers has resulted in early detection of sterilization failures, allowing corrective measures to be taken.

Contact information

Oral Pathology Lab
Dentistry Building, Dalhousie University
5981 University Avenue
PO Box 15000
Halifax, Nova Scotia, Canada
B3H 4R2
Phone: (902) 494-3768
Fax: (902) 494-6411
biosterilizer.monitor@dal.ca

To subscribe to the service, please request a subscription form at biosterilizer.monitor@dal.ca.

The product of the Granatelli/Lotus collaboration was the Lotus 56, the first-ever turbine-powered Lotus car. Like the car driven by Parnelli Jones one year earlier, the 56 would also take advantage of four-wheel drive's extra traction to harness the turbine's power, this time a slightly different STN 6/76 from Pratt & Whitney that generated approximately 500 horsepower. However, that's where the similarities ended.

Chapman's infatuation with weight and aerodynamics resulted in a different layout for the 56, with the engine behind the driver — as opposed to alongside in the earlier Paxton Turbocar — and a radically narrow, doorstop-like wedge shape.

For the 1968 Indy 500, Granatelli and Lotus decided to campaign not one, but four of the Lotus 56s. During practice sessions, one of the cars piloted by Mike Spence set a new track record of 169.555 mph, so the team knew that it had a formidable contender on its hands. Later in the day, Spence took the wheel of a different Lotus 56 which appeared to be underperforming. Unfortunately, Spence was involved in a crash during his troubleshooting test laps in that second car, one which he didn't survive.

[Featured image by The359 via Wikimedia Commons | Cropped and scaled | CC BY-SA 3.0]